Eventide Asset Management’s AnaptysBio ANAB Stock Holding History

Eventide Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-263,748	Closed	-$8.84M	–	206
2024 Q3	$8.84M	Sell	263,748 -304,576	-54%	-$10.4M	0.15%	126
2024 Q2	$14.2M	Buy	568,324 +141,324	+33%	+$3.29M	0.24%	109
2024 Q1	$9.62M	Hold	427,000	–	–	0.15%	127
2023 Q4	$9.15M	Hold	427,000	–	–	0.15%	122
2023 Q3	$7.67M	Buy	+427,000	New	+$8.15M	0.14%	131
2018 Q4	–	Sell	-262,275	Closed	-$26.2M	–	139
2018 Q3	$26.2M	Buy	262,275 +190,275	+264%	+$15.8M	0.96%	37
2018 Q2	$5.12M	Buy	+72,000	New	+$6.04M	0.21%	92

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Eventide Asset Management's ANAB Position: Q4 2024 in Review

Eventide Asset Management sold out of AnaptysBio (ANAB) in Q4 2024, closing a stake of 263,748 shares — an estimated $8.84M sold.

Eventide Asset Management first reported a position in ANAB in Q2 2018 and held it in 7 quarters. The position peaked at $26.2M in Q3 2018. 135 funds tracked by Wall St. Rank hold ANAB as of Q4 2024.

Eventide Asset Management reported no remaining AnaptysBio position as of Q4 2024 after selling out during the quarter.
Eventide Asset Management sold 263,748 AnaptysBio shares in Q4 2024, an estimated $8.84M.
Eventide Asset Management first reported a position in AnaptysBio in Q2 2018 and held it in 7 quarters.
Eventide Asset Management's AnaptysBio position peaked at $26.2M in Q3 2018.
135 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2024.

Based on Eventide Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.